MARKET WIRETradingView • 19h ago
Pulmatrix, Inc. Estimates – NASDAQ:PULMTradingView report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
Why PULM Stock slipped -1.06% Today — RQD Quant Desk Flash
$1.40 -1.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.39
Pulmatrix Inc. (PULM) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $5.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PULM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PULM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Pulmatrix Inc. (NASDAQ: PULM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.40 (-1.06% 1D, market cap $5.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PULM ranks #584 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PULM compare to IMNN and GELS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PULM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMNN (Imunon Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $5.1M) and GELS (Gelteq Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.2M). Among the 5-stock peer group, PULM leads on earnings multiple (N/A) while PULM leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PULM?
▼
Per PULM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001574235), Pulmatrix Inc. generated $0 in revenue (-100.0% YoY), -$5.2M in net income, and -$5.4M in free cash flow against $4.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.39 (-0.38%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PULM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY PULM SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)
FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 45.1 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.38+3.6% Next Q
28
Q2 (-2Q)Grade E$1.43+4.2% Next Q
31
Q3 (-1Q)Grade E$1.49-6% Next Q
33
CurrentGrade D-$1.40-8.3% Hist 90D α
36
Trajectory: E (28) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PULM Turnaround Squeeze
While PULM currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.48) and Max Pain ($1.47) forces dealer call-delta covering toward $5.24.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PULM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PULM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PULM Stock slipped -1.06% Today — RQD Quant Desk Flash
Pulmatrix Inc. (PULM) slipped -1.06% to $1.40, trading at 6% of its 52-week range ($1.16 – $4.99). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 6% of its 52-week range ($1.16 – $4.99) with RSI-14 at 45.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.40 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live PULM Headlines & Catalysts
MARKET WIREStock Titan • 22h ago
Up to 491,607 Pulmatrix (PULM) shares are registered for resale; the company gets no proceeds.Stock Titan report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com UK • 1d ago
Form 4 Pulmatrix Inc For: 30 October By Investing.comInvesting.com UK report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance Australia • 1d ago
Moleculin Biotech, Inc. (MBRX) stock price, news, quote and historyYahoo Finance Australia report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
PULM: Preliminary votes supported all eight proposals, including the Eos merger and related changesTradingView report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Pulmatrix, Inc. SEC Filing (Oct 23, 2026)Stock Titan report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com UK • 1d ago
Form 4 Pulmatrix Inc For: 22 October By Investing.comInvesting.com UK report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMinichart • 1d ago
Pulmatrix Stockholders Approve Eos Merger Share Issuance, Reverse SplitMinichart report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 3d ago
Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat StudyInterim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos’s R&D Facility; Data Support IND-Enabling Development
CATALYSTYahoo • 11d ago
Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived MouseIn naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142)“Speedy,” a PTC-2105-treat
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PULM)
- ✓Walkthrough of PULM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PULM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.87%▼ DESCENDING CHANNEL
2026-11-03O $1.41H $1.41L $1.40C $1.40VOL 9.6K
RES: $1.72SUP: $1.31SMA50: $1.48SMA200: $1.70
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PULM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PULM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PULM. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PULM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PULM)
Health Care Rank #584 of 1016
⚔️ IMNN vs PULM Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PULM vs. IMNN, GELS, ADXN, PCSA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Pulmatrix Inc. (PULM) ranks #584 by composite RQD confidence (36/100, grade D-) and #941 by equity capitalization ($5.1M). Within this direct 5-issuer industry benchmark cohort, PULM leads on earnings valuation at N/A trailing P/E, while PULM leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with PULM at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PULM
ACTIVE
Pulmatrix Inc. | D- | 36/100 | — | — | -35.0% | -1.06% | $5.1M | Benchmark Subject |
| IMNN Imunon Inc. | E | 31/100 | — | — | -35.0% | +9.24% | $5.1M | /imnn-vs-pulm → |
| GELS Gelteq Limited | D+ | 54/100 | — | — | — | -3.14% | $5.2M | /gels-vs-pulm → |
| ADXN Addex Therapeutics Ltd | D | 48/100 | — | — | — | +5.46% | $5.3M | /adxn-vs-pulm → |
| PCSA Processa Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | 0.00% | $5.3M | /pcsa-vs-pulm → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001574235In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pulmatrix Inc. (PULM) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $7.8M , and -100.0% cumulative change since FY2023) , GAAP net income of -$5.2M, operating cash flow of -$5.4M, and free cash flow of -$5.4M (+51.1% YoY). On the balance sheet, PULM closed FY2025 with $4.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$5.2M | -$5.4M | -$5.4M | $4.1M | — |
| FY2024 (FY) | 2024-12-31 | $7.8M | -$9.6M | -$10.7M | -$11.1M | $9.9M | — |
| FY2023 (FY) | 2023-12-31 | $7.3M | -$14.1M | -$16.0M | -$16.0M | — | — |
3. PULM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PULM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Pulmatrix Inc. (NASDAQ: PULM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.40 (-1.06% 1D, market cap $5.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PULM ranks #584 in composite RQD confidence.
How does PULM compare to IMNN and GELS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PULM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMNN (Imunon Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $5.1M) and GELS (Gelteq Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.2M). Among the 5-stock peer group, PULM leads on earnings multiple (N/A) while PULM leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PULM?
Per PULM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001574235), Pulmatrix Inc. generated $0 in revenue (-100.0% YoY), -$5.2M in net income, and -$5.4M in free cash flow against $4.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PULM trading relative to its 50-day, 200-day, and 52-week technical levels?
PULM last traded at $1.40 (-1.06% on volume of 9,596 shares), positioning the stock -5.41% below its 50-day simple moving average ($1.48) and -17.65% below its 200-day simple moving average ($1.70). Across its 52-week range of $1.16 to $4.99, PULM sits at the 6.3% percentile with a 14-day RSI of 45.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.23 to $1.57).
PULM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PULM stock moving today?
Why PULM Stock slipped -1.06% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 36/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
PULM — Pulmatrix Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:53:13Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, PULM scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the Fundamental Cash Engine scores 6/20, reflecting a ROIC of -35% and an FCF yield of 0%; for an investor, this indicates the business is not currently converting capital into cash returns. Whale/13F Flow scores 5/20, pointing to weak institutional accumulation and options positioning. Insider Conviction scores 5/20, based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 10/20, with a Beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 10/20, supported by an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. Taken together, the upside drivers in the source data are limited, while the valuation tradeoff is that the stock trades at a $1.42 price with a $5.2M market capitalization against sustained operating losses; the investor implication is elevated downside risk and fragility rather than a demonstrated cash engine. This is an analytical summary, not personalized advice.
Business
Pulmatrix Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company's market capitalization is recorded as $0.0B. Not available in source data: product lines, customer base, and specific revenue model details.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-5.2M | $-5.2M | N/A | $-5.4M | $4.1M | N/A |
| FY 2024 | $7.8M | $-9.8M | $-9.6M | N/A | $-11.1M | $9.5M | N/A |
| FY 2023 | $7.3M | $-14.7M | $-14.1M | N/A | $-16.0M | N/A | N/A |
Per the SEC financials, the company reported operating losses in every period shown, with FY 2025 revenue at $0.0M and FY 2024 revenue at $7.8M. Gross, operating, and net margins are each recorded at 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with a Debt/Equity ratio of 0.5. Cash declined from $9.5M in FY 2024 to $4.1M in FY 2025 alongside negative free cash flow of $-5.4M.
Recent Catalysts & News Wire Analysis
- Headlines in the news wire reference a registration for resale of up to 491,607 PULM shares, with the company receiving no proceeds.
- Headlines reference preliminary votes supporting all eight proposals, including the Eos merger and related changes.
- Headlines reference a Form 4 filing dated 30 October and an SEC filing dated Oct 23, 2026.
- Headlines reference a Moleculin Biotech (MBRX) stock page, a related-name reference rather than a PULM-specific event.
- Risk watch items: potential dilution from resale registration, pending merger-related changes, and continued operating losses. All news items carry a YELLOW light and MARKET WIRE impact label.
- Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Open Questions
- What is the terms and timing of the Eos merger referenced in the news wire, and how would it change the company's operating profile?
- What is the cash runway given $4.1M in FY 2025 cash against a $-5.4M FCF figure, and how would the resale registration affect share count?
- What drives the FY 2025 revenue decline to $0.0M from $7.8M in FY 2024?
- What is the current debt position, since debt is listed as N/A for all periods?
- What are the company's products, pipeline, and customer relationships, given that none are described in the source data?
PULM Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Pulmatrix Inc. (PULM) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 19h ago
Pulmatrix, Inc. Estimates – NASDAQ:PULM TradingView report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 22h ago
Up to 491,607 Pulmatrix (PULM) shares are registered for resale; the company gets no proceeds. Stock Titan report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 1d ago
Form 4 Pulmatrix Inc For: 30 October By Investing.com Investing.com UK report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Australia • 1d ago
Moleculin Biotech, Inc. (MBRX) stock price, news, quote and history Yahoo Finance Australia report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
PULM: Preliminary votes supported all eight proposals, including the Eos merger and related changes TradingView report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Pulmatrix, Inc. SEC Filing (Oct 23, 2026) Stock Titan report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 1d ago
Form 4 Pulmatrix Inc For: 22 October By Investing.com Investing.com UK report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Minichart • 1d ago
Pulmatrix Stockholders Approve Eos Merger Share Issuance, Reverse Split Minichart report covering Pulmatrix Inc. (PULM) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PULM Bull vs. Bear Conversation Board — What's Your Call at $1.40?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PULM 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $1.25 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is PULM (D- • RQD 36/100) a Buy at $1.42?
Welcome to the PULM (Pulmatrix Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $1.08 (-23.9%)
Spot @ $1.42 Pump the brakes on PULM — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on PULM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Pulmatrix Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1.73 (+21.8%)
Spot @ $1.42 PULM cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on PULM, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.42 (52-wk range $1.16 - $4.99), any beat on forward guidance forces shorts and underweight funds to chase.